A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Background: Currently available treatments for Parkinson's disease (PD) do not slow clinical progression nor target alpha-synuclein, a key protein associated with the disease. Objective: The study objective was to evaluate the efficacy and safety of prasinezumab, a humanized monoclonal antibody that binds aggregated alpha-synuclein, in individuals with early PD. Methods: The PASADENA study is a multicenter, randomized, double-blind, placebo-controlled treatment study. Individuals with early PD, recruited across the US and Europe, received monthly intravenous doses of prasinezumab (1,500 or 4,500 mg) or placebo for a 52-week period (Part 1), followed by a 52-week extension (Part 2) in which all participants received active treatment. Key inclusion criteria were: aged 40-80 years; Hoehn & Yahr (H&Y) Stage I or II; time from diagnosis ≤2 years; having bradykinesia plus one other cardinal sign of PD (e.g., resting tremor, rigidity); DAT-SPECT imaging consistent with PD; and either treatment naïve or on a stable monoamine oxidase B (MAO-B) inhibitor dose. Study design assumptions for sample size and study duration were built using a patient cohort from the Parkinson's Progression Marker Initiative (PPMI). In this report, baseline characteristics are compared between the treatment-naïve and MAO-B inhibitor-treated PASADENA cohorts and between the PASADENA and PPMI populations. Results: Of the 443 patients screened, 316 were enrolled into the PASADENA study between June 2017 and November 2018, with an average age of 59.9 years and 67.4% being male. Mean time from diagnosis at baseline was 10.11 months, with 75.3% in H&Y Stage II. Baseline motor and non-motor symptoms (assessed using Movement Disorder Society-Unified Parkinson's Disease Rating Scale [MDS-UPDRS]) were similar in severity between the MAO-B inhibitor-treated and treatment-naïve PASADENA cohorts (MDS-UPDRS sum of Parts I + II + III [standard deviation (SD)]; 30.21 [11.96], 32.10 [13.20], respectively). The overall PASADENA population (63.6% treatment naïve and 36.4% on MAO-B inhibitor) showed a similar severity in MDS-UPDRS scores (e.g., MDS-UPDRS sum of Parts I + II + III [SD]; 31.41 [12.78], 32.63 [13.04], respectively) to the PPMI cohort (all treatment naïve). Conclusions: The PASADENA study population is suitable to investigate the potential of prasinezumab to slow disease progression in individuals with early PD. Trial Registration: NCT03100149.
['Pagano|Gennaro|G|', 'Boess|Frank G|FG|', 'Taylor|Kirsten I|KI|', 'Ricci|Benedicte|B|', 'Mollenhauer|Brit|B|', 'Poewe|Werner|W|', 'Boulay|Anne|A|', 'Anzures-Cabrera|Judith|J|', 'Vogt|Annamarie|A|', 'Marchesi|Maddalena|M|', 'Post|Anke|A|', 'Nikolcheva|Tania|T|', 'Kinney|Gene G|GG|', 'Zago|Wagner M|WM|', 'Ness|Daniel K|DK|', 'Svoboda|Hanno|H|', 'Britschgi|Markus|M|', 'Ostrowitzki|Susanne|S|', 'Simuni|Tanya|T|', 'Marek|Kenneth|K|', 'Koller|Martin|M|', 'Sevigny|Jeff|J|', 'Doody|Rachelle|R|', 'Fontoura|Paulo|P|', 'Umbricht|Daniel|D|', 'Bonni|Azad|A|', '|||', '|||']
prasinezumab Parkinson's disease monoclonal antibodies disease progression MDS-UPDRS = Movement Disorder Society—Unified Parkinson's Disease Rating Scale Phase II clinical trial alpha-synuclein (α-syn) disease modification treatments